Demis Hassabis just raised $2.1 billion for his AI drug design company. The first human clinical trial has not happened yet. That tension is the entire story. Isomorphic Labs, the London-based AI drug design company founded in 2021 as a Google DeepMind spinout, closed a $2.1 billion Series B on May 12, 2026. The round was led by Thrive Capital, which also led the company’s $600 million Series A in 2025. New investors include Abu Dhabi’s MGX, Singapore’s Temasek, and the UK Sovereign AI Fund.